Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Agreement Between Large Language Model-Generated Treatment Recommendations With Guideline-Based and Tumor Board Decisions in Gastrointestinal Cancer (KITuKo)

14 mai 2026 mis à jour par: Rene Mantke, Medizinische Hochschule Brandenburg Theodor Fontane

Concordance of Large Language Model-Generated Treatment Recommendations With Multidisciplinary Tumor Board and Guideline-Based Decisions in Gastrointestinal Cancer: A Retrospective Cohort Study

The goal of this observational study is to learn whether a computer program can suggest cancer treatments that match expert recommendations for people with gastrointestinal cancer (cancer of the pancreas, stomach, or colon and rectum).

The main questions it aims to answer are:

  • Do the treatment suggestions from the computer program match current medical guidelines?
  • Do these suggestions match decisions made by a multidisciplinary tumor board (a team of cancer specialists)?

Researchers will review existing medical records from people who have already been treated for these cancers. They will enter key clinical information into a computer program that uses artificial intelligence (AI). The program will generate treatment suggestions for each case.

Researchers will then compare these suggestions with:

  • guideline-based treatment recommendations
  • decisions made by the tumor board

This study will help researchers understand whether AI tools could support doctors in making cancer treatment decisions in the future.

Aperçu de l'étude

Description détaillée

Gastrointestinal cancers require complex treatment planning that often involves surgery, systemic therapy, and multidisciplinary coordination. Clinical decision-making is typically guided by evidence-based recommendations and discussed in multidisciplinary tumor boards. However, the increasing complexity of treatment strategies and guideline frameworks can make consistent and reproducible decision-making challenging in routine clinical practice.

Recent advances in artificial intelligence have enabled the development of large language models (LLMs) that can process structured clinical information and generate text-based recommendations. These systems may offer a scalable approach to support clinical workflows, but their ability to produce reliable and clinically appropriate treatment suggestions in oncology remains uncertain.

This study evaluates the performance of an LLM-based system in the context of gastrointestinal oncology using retrospectively collected clinical case data. Structured case summaries derived from routine clinical documentation are used as standardized input. The model generates treatment recommendations under controlled conditions, allowing systematic comparison with established clinical reference standards.

The analysis focuses on the level of agreement between model-generated recommendations and established decision-making frameworks. In addition, the study explores how model performance varies across different clinical scenarios, including varying levels of disease complexity. Particular attention is given to situations in which recommendations differ, in order to better understand potential limitations of the model and identify patterns that may be clinically relevant.

Furthermore, the study examines the consistency of model outputs when the same clinical information is processed multiple times. This provides insight into the stability and reproducibility of the system, which are important considerations for potential real-world use.

The findings of this study are intended to inform the potential role of LLM-based tools as supportive systems in clinical decision-making. The study does not evaluate clinical outcomes or patient benefit, but instead focuses on agreement with established standards and expert-driven decisions as an initial step in assessing feasibility and safety.

Type d'étude

Observationnel

Inscription (Réel)

30

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Brandenburg
      • Brandenburg an der Havel, Brandenburg, Allemagne, 14770
        • University Hospital Brandenburg

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

The study population consists of adult patients with gastrointestinal adenocarcinoma treated at a tertiary care academic center in the Federal State of Brandenburg, Germany. The population is derived from routine clinical practice and includes patients whose cases were evaluated in a multidisciplinary tumor board.

La description

Inclusion Criteria:

  • Histologically confirmed pancreatic, gastric, or colorectal adenocarcinoma
  • Treatment discussed in a multidisciplinary tumor board

Exclusion Criteria:

  • Non-adenocarcinoma histology

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Cancer colorectal
Patients atteints de cancer colorectal
Detailed treatment recommendation according to the official guideline of the Association of the Scientific Medical Societies in Germany (AWMF; Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften),
Structured clinical case summaries were analyzed by a GPT-4-class large language model to generate treatment recommendations.
Detailed treatment recommendation according to the case-specific postoperative tumor board review.
Pancreatic cancer
Patients with pancreatic cancer
Detailed treatment recommendation according to the official guideline of the Association of the Scientific Medical Societies in Germany (AWMF; Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften),
Structured clinical case summaries were analyzed by a GPT-4-class large language model to generate treatment recommendations.
Detailed treatment recommendation according to the case-specific postoperative tumor board review.
Gastric cancer
Patients with gastric cancer
Detailed treatment recommendation according to the official guideline of the Association of the Scientific Medical Societies in Germany (AWMF; Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften),
Structured clinical case summaries were analyzed by a GPT-4-class large language model to generate treatment recommendations.
Detailed treatment recommendation according to the case-specific postoperative tumor board review.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Concordance with guideline-based management
Délai: At the time of multidisciplinary tumor board evaluation up to 4 weeks after surgery
Agreement between LLM-generated recommendations and AWMF guideline-supported treatment strategies
At the time of multidisciplinary tumor board evaluation up to 4 weeks after surgery

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Concordance with multidisciplinary tumor board decisions
Délai: At the time of multidisciplinary tumor board evaluation up to 4 weeks after surgery
Agreement between LLM-generated recommendations and tumor board treatment strategies
At the time of multidisciplinary tumor board evaluation up to 4 weeks after surgery
Reproducibility of LLM recommendations across repeated runs
Délai: At the time of multidisciplinary tumor board evaluation up to 4 weeks after surgery
Structured clinical case vignettes were entered into ChatGPT using a standardized prompt template. To assess within-model reproducibility, each clinical vignette was analyzed in 3 independent model sessions performed on different days using identical clinical input.
At the time of multidisciplinary tumor board evaluation up to 4 weeks after surgery
Characterization of discordant recommendations (e.g., overtreatment, undertreatment)
Délai: At the time of multidisciplinary tumor board evaluation up to 4 weeks after surgery

Overtreatment was defined as an LLM-generated recommendation exceeding the intensity of the reference recommendation.

Undertreatment was defined as omission of a recommended treatment or recommendation of a less intensive strategy.

At the time of multidisciplinary tumor board evaluation up to 4 weeks after surgery

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 janvier 2025

Achèvement primaire (Réel)

1 janvier 2026

Achèvement de l'étude (Réel)

25 février 2026

Dates d'inscription aux études

Première soumission

4 mai 2026

Première soumission répondant aux critères de contrôle qualité

14 mai 2026

Première publication (Réel)

18 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 mai 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

14 mai 2026

Dernière vérification

1 mai 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Individual participant data will not be shared. The dataset consists of retrospective, pseudonymized clinical data from a single institution, and sharing is restricted due to data protection regulations and institutional policies.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner